Changes in the V 3 region of gp 120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR 5 Delta 32 heterozygote
暂无分享,去创建一个
Steven M. Wolinsky | John R. Mascola | Tom Morgan | J. Mascola | John P. Moore | Steven Wolinsky | K. Kunstman | P. Gorry | M. Farzan | P. Clapham | S. Crowe | Joann M. Taylor | Michael Farzan | Andrew Mehle | Geoffrey H. Holm | Paul R. Gorry | Suzanne M. Crowe | Philip Ellery | Dana Gabuzda | Kevin Kunstman | Paul R. Clapham | D. Gabuzda | Rebecca L. Dunfee | Megan E. Mefford | Kristin Agopian | Joann Taylor | Hui Wang | Samantha J. Willey | T. Morgan | Hui Wang | R. Dunfee | K. Agopian | Andrew Mehle | S. Willey | Philip J. Ellery
[1] P. Rose,et al. Variants of Human Immunodeficiency Virus Type 1 That Efficiently Use CCR5 Lacking the Tyrosine-Sulfated Amino Terminus Have Adaptive Mutations in gp120, Including Loss of a Functional N-Glycan , 2005, Journal of Virology.
[2] M. Churchill,et al. Longitudinal analysis of nef/long terminal repeat-deleted HIV-1 in blood and cerebrospinal fluid of a long-term survivor who developed HIV-associated dementia. , 2004, The Journal of infectious diseases.
[3] D. Purcell,et al. Apoptosis induced in synchronized human immunodeficiency virus type 1-infected primary peripheral blood mononuclear cells is detected after the peak of CD4+ T-lymphocyte loss and is dependent on the tropism of the gp120 envelope glycoprotein. , 2004, Virology.
[4] John P. Moore,et al. Alanine Substitutions of Polar and Nonpolar Residues in the Amino-Terminal Domain of CCR5 Differently Impair Entry of Macrophage- and Dualtropic Isolates of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.
[5] R. Koup,et al. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. , 1995, AIDS research and human retroviruses.
[6] R. Weiss,et al. CD4-independent infection by HIV-2 (ROD/B): use of the 7-transmembrane receptors CXCR-4, CCR-3, and V28 for entry. , 1997, Virology.
[7] D. Kabat,et al. Cooperation of Multiple CCR5 Coreceptors Is Required for Infections by Human Immunodeficiency Virus Type 1 , 2000, Journal of Virology.
[8] J. Phair,et al. Persistence of dual-tropic HIV-1 in an individual homozygous for the CCR5 Delta 32 allele. , 2002, Lancet.
[9] M. Roger. Influence of host genes on HIV‐1 disease progression , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[10] J. Albert,et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype , 1997, Journal of virology.
[11] G. Simmons,et al. Primary Human Immunodeficiency Virus Type 2 (HIV-2) Isolates Infect CD4-Negative Cells via CCR5 and CXCR4: Comparison with HIV-1 and Simian Immunodeficiency Virus and Relevance to Cell Tropism In Vivo , 1999, Journal of Virology.
[12] Bette Korber,et al. Structure of a V3-Containing HIV-1 gp120 Core , 2005, Science.
[13] J. Phair,et al. Chemokine Coreceptor Usage by Diverse Primary Isolates of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.
[14] Hua,et al. Identification of , 2000, Journal of insect physiology.
[15] M. Churchill,et al. Longitudinal Analysis of Human Immunodeficiency Virus Type 1 nef/Long Terminal Repeat Sequences in a Cohort of Long-Term Survivors Infected from a Single Source , 2006, Journal of Virology.
[16] William C. Olson,et al. Differential Inhibition of Human Immunodeficiency Virus Type 1 Fusion, gp120 Binding, and CC-Chemokine Activity by Monoclonal Antibodies to CCR5 , 1999, Journal of Virology.
[17] Robyn L Stanfield,et al. Genetic and Phenotypic Analyses of Human Immunodeficiency Virus Type 1 Escape from a Small-Molecule CCR5 Inhibitor , 2004, Journal of Virology.
[18] D. Kerjaschki,et al. The beta-chemokine receptor D6 is expressed by lymphatic endothelium and a subset of vascular tumors. , 2001, The American journal of pathology.
[19] Miriam K. Konkel,et al. The Orphan Seven-Transmembrane Receptor Apj Supports the Entry of Primary T-Cell-Line-Tropic and Dualtropic Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.
[20] J. Sodroski,et al. Loss of a Single N-Linked Glycan Allows CD4-Independent Human Immunodeficiency Virus Type 1 Infection by Altering the Position of the gp120 V1/V2 Variable Loops , 2001, Journal of Virology.
[21] P. Rose,et al. Adaptive Mutations in the V3 Loop of gp120 Enhance Fusogenicity of Human Immunodeficiency Virus Type 1 and Enable Use of a CCR5 Coreceptor That Lacks the Amino-Terminal Sulfated Region , 2001, Journal of Virology.
[22] S. Hammer,et al. Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy. , 2001, The Journal of infectious diseases.
[23] John P. Moore,et al. The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. , 2004, AIDS research and human retroviruses.
[24] J. Bell,et al. Identification of a Subset of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus Strains Able To Exploit an Alternative Coreceptor on Untransformed Human Brain and Lymphoid Cells , 2003, Journal of Virology.
[25] A. Trkola,et al. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS , 1994, Journal of virology.
[26] J. Mascola,et al. Human Immunodeficiency Virus Type 1 Neutralization Measured by Flow Cytometric Quantitation of Single-Round Infection of Primary Human T Cells , 2002, Journal of Virology.
[27] A. Trkola,et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 , 1996, Journal of virology.
[28] A. Trkola,et al. Use of alternate coreceptors on primary cells by two HIV-1 isolates. , 2005, Virology.
[29] D R Burton,et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. , 1994, Science.
[30] O. Nishimura,et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[31] R. Connor,et al. Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals , 1997, The Journal of experimental medicine.
[32] D. Kabat,et al. Polymorphisms in the CCR5 genes of African green monkeys and mice implicate specific amino acids in infections by simian and human immunodeficiency viruses , 1997, Journal of virology.
[33] Steven L Wesselingh,et al. Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome. , 2005, Virology.
[34] V. Georgiev. Virology , 1955, Nature.
[35] Oliver Hartley,et al. V3: HIV's switch-hitter. , 2005, AIDS research and human retroviruses.
[36] J. Sodroski,et al. Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody , 1993, Journal of virology.
[37] H. Schuitemaker,et al. Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression. , 1999, The Journal of infectious diseases.
[38] Joseph Sodroski,et al. Tyrosine Sulfation of the Amino Terminus of CCR5 Facilitates HIV-1 Entry , 1999, Cell.
[39] William C. Olson,et al. Amino-Terminal Substitutions in the CCR5 Coreceptor Impair gp120 Binding and Human Immunodeficiency Virus Type 1 Entry , 1998, Journal of Virology.
[40] J. Albert,et al. Primary Human Immunodeficiency Virus Type 2 (HIV-2) Isolates, Like HIV-1 Isolates, Frequently Use CCR5 but Show Promiscuity in Coreceptor Usage , 1999, Journal of Virology.
[41] H. Hocini,et al. Opposite Effects of IL-10 on the Ability of Dendritic Cells and Macrophages to Replicate Primary CXCR4-Dependent HIV-1 Strains1 , 2001, The Journal of Immunology.
[42] H. Guy,et al. Epitope Mapping of CCR5 Reveals Multiple Conformational States and Distinct but Overlapping Structures Involved in Chemokine and Coreceptor Function* , 1999, The Journal of Biological Chemistry.
[43] E. Rosenberg,et al. Functional Mimicry of a Human Immunodeficiency Virus Type 1 Coreceptor by a Neutralizing Monoclonal Antibody , 2005, Journal of Virology.
[44] W. Paxton,et al. Intrapatient Alterations in the Human Immunodeficiency Virus Type 1 gp120 V1V2 and V3 Regions Differentially Modulate Coreceptor Usage, Virus Inhibition by CC/CXC Chemokines, Soluble CD4, and the b12 and 2G12 Monoclonal Antibodies , 2004, Journal of Virology.
[45] R. Doms,et al. An Orphan Seven-Transmembrane Domain Receptor Expressed Widely in the Brain Functions as a Coreceptor for Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus , 1998, Journal of Virology.
[46] J. Sodroski,et al. A Tyrosine-Rich Region in the N Terminus of CCR5 Is Important for Human Immunodeficiency Virus Type 1 Entry and Mediates an Association between gp120 and CCR5 , 1998, Journal of Virology.
[47] R. Nibbs,et al. Cloning and Characterization of a Novel Promiscuous Human β-Chemokine Receptor D6* , 1997, The Journal of Biological Chemistry.
[48] J. Margolick,et al. Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of HIV-infected long-term nonprogressors. , 1997, The Journal of clinical investigation.
[49] Steven M. Wolinsky,et al. The role of a mutant CCR5 allele in HIV–1 transmission and disease progression , 1996, Nature Medicine.
[50] A. Iversen,et al. Heterozygosity for a deletion in the CKR‐5 gene leads to prolonged AIDS‐free survival and slower CD4 T‐cell decline in a cohort of HIV‐seropositive individuals , 1997, AIDS.
[51] Susan Zolla-Pazner,et al. A Variable Region 3 (V3) Mutation Determines a Global Neutralization Phenotype and CD4-Independent Infectivity of a Human Immunodeficiency Virus Type 1 Envelope Associated with a Broadly Cross-Reactive, Primary Virus-Neutralizing Antibody Response , 2002, Journal of Virology.
[52] S. Lewin,et al. Enhanced Replicative Capacity and Pathogenicity of HIV-1 Isolated From Individuals Infected With Drug-Resistant Virus and Declining CD4+ T-Cell Counts , 2005, Journal of acquired immune deficiency syndromes.
[53] J J Goedert,et al. Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene , 1996, Science.
[54] John P. Moore,et al. Increased CCR5 Affinity and Reduced CCR5/CD4 Dependence of a Neurovirulent Primary Human Immunodeficiency Virus Type 1 Isolate , 2002, Journal of Virology.
[55] A. Trkola,et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG , 1995, Journal of virology.
[56] J. Moore,et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor , 1998, Nature Medicine.
[57] J. Farber,et al. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. , 1999, Annual review of immunology.
[58] D R Burton,et al. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[59] E. De Clercq,et al. CXCR4 as a Functional Coreceptor for Human Immunodeficiency Virus Type 1 Infection of Primary Macrophages , 1998, Journal of Virology.
[60] R. Doms,et al. The plasma membrane as a combat zone in the HIV battlefield. , 2000, Genes & development.
[61] J. S. Sullivan,et al. Genomic Structure of an Attenuated Quasi Species of HIV-1 from a Blood Transfusion Donor and Recipients , 1995, Science.
[62] E. De Clercq,et al. Macrophage Tropism of Human Immunodeficiency Virus Type 1 Isolates from Brain and Lymphoid Tissues Predicts Neurotropism Independent of Coreceptor Specificity , 2001, Journal of Virology.
[63] Ying Sun,et al. The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates , 1996, Cell.
[64] S. Oka,et al. In vivo sequence variability of human immunodeficiency virus type 1 envelope gp120: association of V2 extension with slow disease progression , 1997, Journal of virology.
[65] E. Clercq,et al. Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4 , 1997, The Journal of experimental medicine.
[66] J J Goedert,et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. , 1997, Science.
[67] J L Sullivan,et al. Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. , 1995, The New England journal of medicine.
[68] Robin A. Weiss,et al. The Promiscuous CC Chemokine Receptor D6 Is a Functional Coreceptor for Primary Isolates of Human Immunodeficiency Virus Type 1 (HIV-1) and HIV-2 on Astrocytes , 2005, Journal of Virology.
[69] Marc Parmentier,et al. Regions in β-Chemokine Receptors CCR5 and CCR2b That Determine HIV-1 Cofactor Specificity , 1996, Cell.
[70] J. Sodroski,et al. Envelope Glycoprotein Determinants of Increased Fusogenicity in a Pathogenic Simian-Human Immunodeficiency Virus (SHIV-KB9) Passaged In Vivo , 2000, Journal of Virology.
[71] M. Kavanaugh,et al. A Critical Site in the Core of the CCR5 Chemokine Receptor Required for Binding and Infectivity of Human Immunodeficiency Virus Type 1* , 1999, The Journal of Biological Chemistry.
[72] A. Trkola,et al. Genetic Subtype-Independent Inhibition of Human Immunodeficiency Virus Type 1 Replication by CC and CXC Chemokines , 1998, Journal of Virology.
[73] R. Doms,et al. Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses , 1997, Journal of virology.
[74] L. Ratner,et al. Human Immunodeficiency Virus Type 1 Coreceptor Switching: V1/V2 Gain-of-Fitness Mutations Compensate for V3 Loss-of-Fitness Mutations , 2006, Journal of Virology.
[75] Ying Sun,et al. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. , 1998, Science.
[76] J. Mascola,et al. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression , 1997, Nature Medicine.
[77] S. O’Brien,et al. The effect of genetic variation in chemokines and their receptorson HIV transmission and progression to AIDS , 2000, Immunological reviews.
[78] N. Saksena,et al. HIV-1 strains from a cohort of American subjects reveal the presence of a V2 region extension unique to slow progressors and non-progressors , 2000, AIDS.